



**LETTER OF ANNOUNCEMENT**  
**Happy birthday EMVS! The European Medicines Verification System's second anniversary**

9<sup>th</sup> February 2021

Two years to the day, the European Medicines Verification System (EMVS) went live across Europe on 9<sup>th</sup> February 2019.

The first of its kind—in terms of its Stakeholder-driven model<sup>1</sup>, interoperability and scale—the EMVS enables end-to-end verification of prescription medicines and is designed to uphold patient safety by preventing falsified medicines from entering the legal supply chain.

The system will continue to be pivotal in the months and years ahead regarding the Falsified Medicines Directive (FMD) and Delegated Regulation (DR). In the last year, EMVO has dealt with challenges such as the effect of Brexit on the EMVS, Covid-19 vaccines and other treatments' rollout and their impact on the EMVS, as well as the ongoing collective mission to reduce alerts.

However, we would like to thank our Stakeholders, the National Medicines Verification Organisations (NMVOs), Marketing Authorisation Holders (MAHs)/On-Boarding Partners (OBPs), the authorities and end-users (pharmacies, hospitals, or wholesales), for making the system what it is today.

Although there is still plenty of work to be done, EMVO is working together with our partners in the healthcare community to fulfil our role of focusing on patient safety. At the same time, the EMVS is a system that benefits millions of Europeans behind the scenes, with patients safe in the knowledge that they are accessing legitimate prescription medicines.

Andreas Walter, General Manager of EMVO, would like to thank all those involved so far personally: “EMVO and the NMVOs have been working faithfully on the EMVS (via the EU Hub and NMVSs) to ensure that we have a system that fulfils our mission of protecting the supply chain from the entry of falsified medicines. EMVO will continue strengthening key priorities, such as EMVS operational excellence, and maintaining and enhancing system stability. Another area we are focusing on is supporting all users to be compliant and fully aligned with the appropriate legislation. It was a tough year for everyone, but by working together, we can overcome any challenges the EMVS may encounter in the future.”

To find out more about EMVO, the EMVS and our ongoing mission, please visit [our website](#) or social media channels.

**More details**

<sup>1</sup>EMVO Stakeholders:



- European Federation of Pharmaceutical Industries and Associations <https://www.efpia.eu/>
- Medicines for Europe <https://www.medicinesforeurope.com/>
- Affordable Medicines Europe <https://affordablemedicines.eu/>
- European Healthcare Distribution Association <http://girp.eu/>
- Pharmaceutical Group of the European Union <https://www.pgeu.eu/en/>
- European Association of Hospital Pharmacists <http://www.eahp.eu/>
- European Hospital and Healthcare Federation <http://www.hope.be/>

In the event of any questions or uncertainty, please do not hesitate to contact our Helpdesk:

Tel. Helpdesk: **+32 (0)2 657 00 08**

E-Mail: [helpdesk@emvo-medicines.eu](mailto:helpdesk@emvo-medicines.eu)

#### **EMVO Team**

#### **European Medicines Verification Organisation**

[www.emvo-medicines.eu](http://www.emvo-medicines.eu)

[helpdesk@emvo-medicines.eu](mailto:helpdesk@emvo-medicines.eu)

EMVO © 2021. All rights reserved.